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Deficits in the basal ganglia pathways modulating cortical motor activity underlie both Parkinson disease (PD) and Huntington dis-
ease (HD). Phosphodiesterase 10A (PDE10A) is enriched in the striatum, and animal data suggest that it is a key regulator of this cir-
cuitry. Here, we report on germline PDE10A mutations in eight individuals from two families affected by a hyperkinetic movement
disorder due to homozygous mutations c.320A>G (p.Tyr107Cys) and c.346G>C (p.Ala116Pro). Both mutations lead to a reduction in
PDE10A levels in recombinant cellular systems, and critically, positron-emission-tomography (PET) studies with a specific PDE10A
ligand confirmed that the p.Tyr107Cys variant also reduced striatal PDE10A levels in one of the affected individuals. A knock-in
mouse model carrying the homologous p.Tyr97Cys variant had decreased striatal PDE10A and also displayed motor abnormalities.
Striatal preparations from this animal had an impaired capacity to degrade cyclic adenosine monophosphate (cAMP) and a blunted
pharmacological response to PDE10A inhibitors. These observations highlight the critical role of PDE10A in motor control across
species.Introduction
Cyclic adenosine monophosphate (cAMP) and cyclic gua-
nosine monophosphate (cGMP) are essential second
messengers regulating multiple signaling pathways in
virtually all cell types.1 Intracellular levels are finely
regulated by cyclic nucleotide phosphodiesterases (PDEs),
which degrade cAMP and cGMP by hydrolysis of both
cAMP and cGMP to the corresponding nucleoside 50 mono-
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in the medium spiny neurons (MSNs) of the corpus stria-
tum.3 The underlying pathology of the classic movement
disorders Parkinson disease (PD [MIM: 168600]) and Hun-
tington disease (HD [MIM: 143100]) focuses on a loss of
dopamine-producing cells in the substantia nigra in PD
and striatal MSNs in HD.4,5 This results in dysregulated
cortical striatal-thalamic connections, contributing to
both motor and cognitive symptoms.6,7 PDE10A modu-
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Figure 1. Clinical Data on the Two Affected Families and Data on PDE10A Levels in HEK293 Cells
(A) Pedigrees of the two families. Affected individuals are shaded, and asterisks indicate that DNA was obtained for genetic analysis.
(B) Schematic diagram of PDE10A. The variants in the GAF-A domain are highlighted, and high conservation of the amino acids is
shown across species.
(C) The level of PDE10A was reduced in an individual with a PDE10A mutation. 11C-IMA107 BPND parametric images derived from 12
healthy control individuals (left) and family 1 individual IV:2 (right) in stereotaxic space are overlaid onto the T1-weighted Montreal
Neurological Institute template (representing a brain of average shape) and show significant loss of striatal and pallidal PDE10A signal
in IV:2. The scatterplot shows 11C- IMA107 BPND values in the caudate and putamen for healthy control individuals (n ¼ 12) and family
1 individual IV:2. Solid lines represent mean 11C-IMA107 BPND values þ 1 SD for healthy control individuals and IV:2.
(D) PDE10A levels compared amongWT, p.Tyr107Cys, and p.Ala116Pro proteins inHEK293 cells (right) and representative immunoblots
fromPDE10A transfection experiments (left). Levels ofWTandmutant PDE10Aweremeasured inHEK293 cells by immunoblotting using
a specific PDE10A polyclonal antibody (Rbg426v2). The PDE10A band is highlighted with an arrowhead. The amount ofmutant proteins
was lower than that of theWT.Quantification of PDE10A in transfectedHEK293 cells was normalized toGAPDH levels. Experimentswere
replicated four times with four technical replicates per experiment. Data are presented as a group mean5 SEM. ***p < 0.001.activation of dopamine receptors D1 and D2, by degrading
cyclic nucleotides and in animal models regulates the basal
ganglia circuitry.8,9 These observations have stimulated
extensive research into PDE10A as a therapeutic target,10
despite little physiological data in humans. By a com-
bination of homozygosity mapping and whole-exome
sequencing (WES), we identified biallelic missense variants
in two families affected by a hyperkinetic movement disor-
der. Cellular modeling of the variants revealed lower
PDE10A levels in cells expressing the mutant than in cells
expressing the wild-type (WT). Crucially, this recapitulated
our observations in one of the individuals, who showed a
marked loss of striatal PDE01A by positron-emission-to-
mography (PET) scanning. In a knock-in (KI)mousemodel,
we recapitulated the loss of striatal PDE10A, and the mice
also displayed a motor phenotype. This suggests that there
is strong back-translation of the human gene-phenotype
findings in individuals with biallelic PDE10Amutations.736 The American Journal of Human Genetics 98, 735–743, April 7, 2Subjects and Methods
Subject Evaluation
The families provided signed informed consent to participate
in studies approved by the Leeds East research ethics committee
(07/H1306/113; family 1) and by the ethics committee of the
Oulu University Hospital (EETTMK 51/2008; family 2).
Two individuals underwent video recordings for further docu-
mentation of their movement disorders (Movies S1 and S2).
Two families affected by a distinct movement disorder were
independently ascertained and investigated (Figure 1A). Individ-
ual IV:2 (family 1) underwent a PET scan with [11C]IMA107, a
selective PDE10A PET radiotracer, allowing a robust quantification
of PDE10A levels.
Neuroimaging Evaluation
Image Acquisition
PET and MRI scans were performed at Imanova. After providing
written informed consent, participants were instructed to refrain016
from caffeine, tobacco, and alcohol for at least 12 hr before scan-
ning. Healthy control individuals were recruited as part of an
ongoing study.11 Subjects were positioned supine, and head posi-
tion was maintained as previously described.11 All participants
were scanned on a Siemens Biograph HI-REZ 6 PET-CT scanner
after the injection of an intravenous bolus of ~250 MBq [11C]
IMA107. Dynamic emission data were acquired continuously for
90 min after the injection of [11C]IMA107. The dynamic images
were reconstructed into 26 frames (8 3 15 s, 3 3 60 s, 5 3 120 s,
5 3 300 s, and 5 3 600 s) with in-house software and a filtered
back-projection algorithm (direct inverse Fourier transform) with
a 128 3 128 matrix and 2.63 zoom, producing images with
isotropic voxel size of 2 3 2 3 2 mm3 and a transaxial Gaussian
filter of 5 mm.
MRI scans were acquired with a 32-channel head coil on a
Siemens MAGNETOM Verio 3T MRI scanner and included (1) a
T1-weighted magnetization-prepared rapid gradient-echo
(MPRAGE) sequence (time repetition [TR] ¼ 2,300 ms, time echo
[TE] ¼ 2.98 ms, flip angle ¼ 9, time to inversion [TI] ¼ 900 ms,
and matrix ¼ 240 3 256) for co-registration with the PET images
and (2) fast GM T1 inversion recovery (FGATIR; TR ¼ 3,000 ms,
TE ¼ 2.96 ms, flip angle ¼ 8, TI ¼ 409 ms, and matrix ¼ 240 3
256) and fluid and WM suppression (FLAWS; TR ¼ 5,000 ms, TE
¼ 2.94 ms, flip angle ¼ 5, TI ¼ 409/1,100 ms, and matrix ¼
240 3 256) sequences for improving delineation of subcortical
brain regions. All sequences used a 1 mm3 voxel size, anteroposte-
rior phase-encoding direction, and symmetric echo.
Processing of [11C]IMA107 PET Data
Data analysis was performed with the MIAKAT software package
(v.3.3.8, Imanova). Image processing and kinetic modeling of
[11C]IMA107 PET data were blind to subject groups and per-
formed with a standard template of regions of interest (see Nicco-
lini et al.12 for a full description). The primary outcome measure
was the non-displaceable binding potential (BPND) of [
11C]
IMA107 in the striatum, which is proportional to the ratio of
the Bmax for PDE10A to the dissociation constant of [
11C]
IMA107 for PDE10A.Genetic Analysis
In view of the consanguinity in both families, genetic analysis was
performed under a recessive model. In family 1, we performed a
genome-wide homozygosity scan by using the Affymetrix Human
SNP Array 6.0 on DNA from four affected and two unaffected
individuals. Genotype data were analyzed with AutoSNPa and
IBDfinder software.13,14
Two affected individuals from family 2 were investigated by
chromosomal microarray on DNA extracted from fibroblasts
with a 50-mer oligochip (HumanCytoSNP-12 v.2.1 BeadChip,
Illumina). Analysis was performed with both GenomeStudio
(hg19) and KaryoStudio (hg18) programs (Illumina).WES
Analyses for Family 1
Alignment and Variant Calling. Target capture was performed with
the Agilent SureSelect Human All Exon v.4 exome enrichment
kit according to the manufacturer’s standard protocol. Sequencing
of 150-bp paired-end reads was performed with an Illumina
MiSeq. Reads were aligned to GRCh37 with Novoalign (Novocraft
Technologies) and processed with the Genome Analysis Toolkit
(GATK) and Picard (see Web Resources) for realignment of short
indels and removal of duplicate reads. Depth of coverage of theThe Amconsensus coding sequence (CCDS) was assessed with GATK,
which showed that >94% of CCDS bases were covered by at least
five good-quality reads (minimum Phred-like base quality of 17
and minimum mapping quality of 20). Single-nucleotide variants
(SNVs) and indels were called with the GATK UnifiedGenotyper
feature.15,16
Filtering. Custom Perl scripts were used for removing variants
present in dbSNP132 or with a minor allele frequency R 0.1%
and for annotating functional consequences. We called variants
in the autozygous region only with a minimum Phred-like geno-
type quality of 30 and selected for indels within coding regions,
non-synonymous SNVs, and splice-site variants. Variants present
in the 1000 Genomes dataset (November 2011), the National
Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Proj-
ect (ESP) Exome Variant Server, and another 2,500 ethnically
matched in-house exomes were also removed.
Analyses for Family 2
Target capture was performed with the Agilent SureSelect Human
All Exon v.4.1 according to the manufacturer’s standard protocol.
Sequencing was performed on the Illumina GAIIx instrument,
generating 100 bp paired-end reads. In brief, the Burrows-Wheeler
Aligner (v.0.5.9) was used to align raw reads against the reference
human genome (NCBI Genome build GRCh37).17 Local realign-
ment around indels and coverage assessment were performed
with GATK,16 and removal of duplicate reads was performed with
Picard Tools (v.1.53). A mean coverage of 1273 was obtained for
all CCDS exons. The positions of variants on the genome were de-
tected by SAMtools (v.0.1.17).18 Only variants coveredwith at least
five reads and a quality score higher than 20 were considered. Sub-
sequently, ANNOVARwas used for assigning annotations to the list
of detected variants.19 To determine potential candidate variants,
we focused on likely protein-damaging variants (frameshift, indel,
nonsense, missense, and canonical splice-site variants) and dis-
carded any variants with an allele frequency > 1% in the ExAC
Browser or our in-house exome database (~1,000 exomes). We
also removed all variants seen as homozygous in the ExACBrowser.HEK293 Cell Transfection Experiments
HEK293 cells were transfected with human PDE10A (WT,
c.320A>G, or c.346G>C) in the pcDNA3.1 vector with the use
of Lipofectamine 2000 (Life Technologies 11668-019) according
to the manufacturer’s instructions. Samples for protein analysis
were harvested after 24 hr. For every million cells plated on a
10 cm dish, 2 ug of plasmid and 30 ml of Lipofectamine 2000
were used. Lysates were analyzed by immunoblot as described
below.Construction of a PDE10A p.Tyr97Cys Targeting
Vector and Targeted Murine Embryonic Stem Cells
We constructed a murine Pde10a (MGI: 1345143) targeting vector
to create the p.Tyr97Cys variant, which is homologous to the hu-
man p.Tyr107Cys variant. Red/ET recombineering technology20
was used to target a loxP-flanked neomycin cassette into intron 4
of the Pde10a locus along with the TAT:TGT codon mutation in
exon 4 of a murine bacterial artificial clone (BAC) (RP23-67C3,
Invitrogen). Again via Red/ET recombineering, we cloned approx-
imately 11 kb of the Pde10a locus, including the newly introduced
neomycin cassette along with the p.Tyr97Cys genetic modifica-
tion, from the BAC into a pUC57 plasmid to generate the final
sequence-confirmed targeting vector. 50 and 30 homology arms
were 5.4 and 5.5 kb, respectively (Figure S4).erican Journal of Human Genetics 98, 735–743, April 7, 2016 737
The linearized PDE10A p.Tyr97Cys targeting vector was electro-
porated into murine Bruce4 embryonic stem (ES) cells (from Colin
Stewart, National Cancer Institute), which were grown according
to standard procedures previously described.21 After G418 selec-
tion, correctly targeted homologous recombinant ES cell clones
were identified by Southern blot analysis. A probe outside of the
50 homology arm was used in conjunction with MscI-digested ES
cell genomic DNA. With this strategy, the endogenous WT allele
yielded a band of ~11 kb, whereas the targeted allele revealed a pre-
dicted RFLP of ~8 kb as a result of the introduction of a novel MscI
site from the PDE10A p.Tyr97Cys targeting vector. To ensure that
correct homologous recombination occurred at the 30 end, we
confirmed targeting by Southern with BamHI-digested ES cell
genomic DNA in combination with a probe external to the 30
homology arm.Generating KI Mice Carrying PDE10A p.Tyr97Cys
Targeted ES cells carrying the PDE10A p.Tyr97Cys variant with a
normal 40XY karyotype (Coriell Institute for Medical Research)
were microinjected into BALB/c blastocyst-stage embryos (Charles
River Laboratories) according to standard procedures previously
described.22 Resulting chimeric males were mated to EIIa-Cre
transgenic females for the generation of offspring heterozygous
for PDE10A p.Tyr97Cys in the germline and free of the neomycin
selection cassette. Offspring from these and all subsequent mat-
ings were genotyped by qPCR analysis at Transnetyx; offspring
with homozygous KI of PDE10A p.Tyr97Cys along with WT con-
trols were then generated from heterozygous mating pairs. The
Pfizer Institutional Animal Care and Use Committee reviewed
and approved the animal use in these studies. The animal care
and use program is fully accredited by the Association for Assess-
ment and Accreditation of Laboratory Animal Care International.Behavioral Phenotyping of KI Mice Carrying
p.Tyr97Cys
Upon arrival at the animal facility, separate cohorts of young
(4–5 weeks) and adult (7–10 weeks) WT/WT (WT), WT/KI (HET),
and KI/KI (KI) male mice (n ¼ 7–13 per genotype) were individu-
ally housed in standard ventilated caging on a 12/12 hr light/
dark cycle (lights on at 6:00 a.m.) and were provided with food
and water ad libitum. Mice were acclimatized for a minimum of
5 days prior to testing. Mice were subjected to a battery of behav-
ioral tests during the light cycle with a minimum 2 day inter-test
interval (ITI). Mice from the young cohort were maintained in
the facility at the conclusion of initial phenotyping until they
reached 24–25 weeks of age, at which time they were re-evaluated
as aged mice. The phenotyping battery consisted of the SHIRPA
protocol23 and then the following tests in order.
Rotarod
Balance and coordination were evaluated in test mice with an
automated accelerating rotarod (Rotamex; Columbus Instru-
ments). The rotarod consisted of four lanes separated by a visual
barrier with a rotating spindle (3.0 cm diameter) elevated
44.5 cm from the floor. Infrared beams placed at the level of the
spindle detected the presence or absence of the animal on the
spindle. Mice were placed on the rotarod at 4 RPM, which was
accelerated at a rate of 1 RPM per 8 s throughout a 5 min trial
period. Mice were subjected to five consecutive trials separated
by a 30 5 5 min ITI. Trials ended at the conclusion of the 5 min
trial period or when the mouse fell from the rod. Latency to
fall (s) was recorded and analyzed by a two-way repeated-measures738 The American Journal of Human Genetics 98, 735–743, April 7, 2ANOVA (genotype3 trial) with GraphPad Prism v.5.0 and Bonfer-
roni post hoc tests as appropriate.
Open-Field Activity
VersaMax chambers for monitoring animal activity (AccuScan
Instruments) were used for assessing alterations in general explor-
atory behavior. Chambers were housed in a testing room with
environmental conditions similar to those of the housing room
(~400 lux and 60–70 dB background noise). Mice were habituated
to the testing room for a minimum 60 min habituation period
prior to testing. After habituation, mice were placed into individ-
ual open-field chambers, and behavior was recorded in the open
field (40 3 40 3 40 cm) for a 60 min period. Infrared beams
captured total distance traveled (cm) and rearing behavior (vertical
activity measured by beam breaks). Data were analyzed by two-
way repeated-measures ANOVA (genotype3 time) with GraphPad
Prism v.5.0 and Bonferroni post hoc tests as appropriate.
Dynamic Weight Bearing
The dynamic weight-bearing (DWB) test is a type of incapacitance
test used tomeasure postural equilibrium in freelymoving rodents
(BioSeb). The apparatus consists of a Plexiglas enclosure (22 3
22 3 30 cm) with a floor instrument cage and video-camera inter-
face that can independently measure the weight borne by each
limb of the freely moving subject. Mice were placed individually
in the apparatus for a 3–5 min period (no acclimation period).
A trained observer blind to genotype mapped left and right hind-
paws and forepaws according to the video. Raw paw-pressure
values interfaced with video data were analyzed by DWB software.
Data for individual measures were analyzed by one-way ANOVA
with Dunnett’s post hoc test as appropriate.
Immunoblotting
Mouse striatal tissue or HEK293 cells were lysed in RIPA buffer
(50 mM Tris-HCl [pH 8.0], 150 mM NaCl, 1.0% NP-40, 0.5%
sodium deoxycholate, and 0.1% SDS supplemented with protease
and phosphatase inhibitor cocktails) and homogenized by brief
sonication. Equal amounts of protein were separated in a reducing
4%–12% Tris-Glycine gel (Invitrogen) and blotted onto a nitrocel-
lulose membrane (Hybond-ECL, GE). Protein levels were deter-
mined by fluorescent or ECl-based immunoblotting followed
by densitometric analysis (Li-Cor-Odyssey, ImageJ). The following
antibodies were used:mouse-anti-PDE10A-24F3.F11,24 rabbit-anti-
PDE10A-426v2,25 mouse-anti-GAPDH-MAB374 (Millipore), goat-
anti-Rabbit-IRDye680 (Li-Cor), goat-anti-Mouse-IRDye800 (Li-
Cor), and donkey-anti-Mouse-HRP (Jackson). Data were analyzed
by one-way ANOVA with GraphPad Prism v.5.0.Results
Clinical Characterization of Families
Family 1 is a consanguineous UK family of Pakistani origin
(Figure 1A, left). All affected individuals presented in child-
hood (mean age of 3 months) with axial hypotonia and
a generalized hyperkinetic movement disorder. This was
characterized by dyskinesia of the limbs and trunk. At
times, the hyperkinetic movements had a jerky quality,
and intermittent chorea and ballismus were also present.
Facial involvement was evident with orolingual dyski-
nesia, drooling, and dysarthria. The severity of the hyper-
kinesis varies considerably within the family, and the old-
est individual is the least affected. Cognitive performance016
is preserved, and all affected individuals graduated from
high school.
Family 2 is from northern Finland (Figure 1A, right). Two
affected boys were born to healthy first-cousin parents.
Both boys show mild cognitive delay and severe axial hy-
potonia. From early infancy, they presented with a gener-
alized hyperkinetic movement disorder characterized by
dyskinesia affecting all four limbs and the trunk and face
(Movies S1 and S2). Expressive language was not evident
until 7 years of age, and both individuals have persistent
dysarthria.
IV:2 is more severely affected; he has had focal epilepsy
since 3.5 years of age and feeds via a gastrostomy tube.
Further clinical details can be found in Table S1.
In both families, array comparative genomic hybridiza-
tion, muscle biopsy, and, crucially, brain MRIs in individ-
uals IV:2, V:2, and V:3 from family 1 and both of the
affected individuals from family 2 were normal. Further
details are provided in the Supplemental Note.
Genetic Analyses Reveal Missense Mutations in
PDE10A
In family 1, genome-wide SNP analysis revealed a single 2.6
Mb region of concordant homozygosity on 6q26. WES
revealed one potentially pathogenic variant within the
homozygous region: c.320A>G (p.Tyr107Cys) in exon 4
of PDE10A (GenBank: NM_001130690.2) (Figure 1B). In
family 2, there were 16 common autozygous regions, the
three largest of which clustered on 6q26. WES revealed a
single potentially deleteriousmutationwithin thehomozy-
gous segments: c.346G>C (p.Ala116Pro), also in exon 4 of
PDE10A (Figure 1B). Neither variant was present in dbSNP,
1000 Genomes, the NHLBI ESP, or our in-house exome da-
tabases. Both individual variants are fully conserved back
to Danio rerio (Figure 1B), lie within a region of very high
conservation, and are predicted to be deleterious.26 Sanger
sequencing confirmed the presence of the variants and
that they segregate with the phenotype in the families.
PDE10A Levels Are Decreased in an Individual with
the p.Tyr107Cys Variant
Given that there are now well-characterized PET ligands
for PDE10A, we wanted to understand the impact of the
mutations on PDE10A levels in the human brain. Because
of ethical considerations, we were able to study only indi-
vidual IV:2 from family 1 in this manner. PDE10A PET
signal was robustly lower in this individual than in healthy
control individuals (Figure 1C), and quantitative analysis
revealed a 70% reduction in PDE10A in all basal ganglia
regions (Figure 1C and Figure S1). An accompanying struc-
tural MRI showed that this loss of PDE10A signal was not
due to loss of striatal volume (see Figure S2).
Effect of PDE10A Mutations on PDE10A Levels in
HEK293 Cells
To evaluate the functional consequence of the PDE10Amu-
tations, we expressed WT and mutant PDE10A (c.320A>GThe Amand c.346G>C) in HEK293 cells. PDE10A levels were inves-
tigated by immunoblotting using validated antibodies (see
Figure S3). A significant decrease in PDE10A levels was asso-
ciated with both mutations (Figure 1D), consistent with
the human PET study above. The reduction of PDE10A
p.Ala116Pro was greater than that of PDE10A p.Tyr107Cys,
perhaps reflecting the more severe phenotype seen in the
Finnish family.A Mouse Model Carrying PDE10A p.Tyr97Cys,
Homologous to Human PDE10A p.Tyr107Cys,
Displays Deficits in Motor Control
We next investigated KI mice carrying the PDE10A variant
p.Tyr97Cys, which is homologous to the human
p.Tyr107Cys variant (Figure S4). SHIRPA phenotyping of
the HET and KI mice did not reveal any behavioral pheno-
types.23 We therefore investigated locomotor activity in
young (4–5 weeks of age), adult (7–10 weeks of age), and
old animals (24–25 weeks of age). Data for adult mice are
shown in Figures 2A–2C, and data for young and old
mice are presented in Figure S5.
KI mice showed significantly less total distance traveled
(Figure 2A and Figure S5, left) and rearing behavior
(Figure 2B and Figure S5, middle) than did age-matched
HET and WT controls. Relative to age-matched HET and
WT controls, KI mice also demonstrated a reduced ability
tomaintain their balance on an accelerating rotarod (Figure
2C and Figure S5, right). In a DWB assay, relative to both
HET and WT littermate controls, KI mice demonstrated
statistically significant increases in forepawbearingweight,
whereas hindpaw weights were reduced (Figure S6).
Together, these data show that KI mice display motor
abnormalities.p.Tyr97Cys KIMice Have Reduced Levels of PDE10A in
the Striatum
Consistent with the PET data on human PDE10A and the
protein studies inHEK293 cells, KImice showed lower stria-
tal protein levels than did age-matchedWT (p< 0.001) and
HET animals (p < 0.001; Figures 2D and 2E). Striatal tissue
from KI mice showed lower levels of PDE10A activity than
did that of age-matched WT (p < 0.001) and HET animals
(p < 0.01; Figure 2F). Inhibition of PDE10A is known to
lead to an increase in levels of phosphorylated CREB
(pCREB). After administration of the potent, selective
PDE10A inhibitor MP-10, WT and HET mice showed
400% more (p < 0.001) striatal pCREB than did vehicle-
treated mice. No such increase in pCREB was observed in
the KI mice, confirming that the biallelic PDE10A variant
reduces downstream pCREB signaling (Figure 2G).Discussion
We have described eight individuals from two families
affected by an early-onset hyperkinetic movement disor-
der associated with mutations in PDE10A. Expression oferican Journal of Human Genetics 98, 735–743, April 7, 2016 739
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Figure 2. Adult KI Mice with PDE10A p.Tyr97Cys Demonstrate Motor Abnormalities and Reduced Striatal PDE10A Levels and
Function
(A and B) Total distance traveled (A) and rearing behavior (B) as measured by vertical activity were recorded and analyzed by a two-way
repeated-measures ANOVA (genotype 3 trial) with GraphPad Prism v.5.0 and Bonferroni post hoc tests as appropriate. All data are pre-
sented as the group mean5 SEM. n ¼ 13, 12, and 11 for WT (WT/WT), HET (WT/KI), and KI (KI/KI) mice, respectively. All adult mice
were 7–10 weeks old. *p < 0.05.
(C) Latency to fall (s) was recorded and analyzed by a two-way repeated-measures ANOVA (genotype3 trial) with GraphPad Prism v.5.0
and Bonferroni post hoc tests as appropriate. KI mice carrying the homologous p.Tyr97Cys variant showed a hypokinetic phenotype,
deficits in rearing activity, and deficits in performance on the rotorod. *p < 0.05.
(D) The PDE10A p.Tyr97Cys variant led to a reduction in PDE10A. Representative immunoblots of striatal protein lysates from adult
mice from each genotype (n ¼ 5 for WT, HET, and KI) were analyzed by immunoblotting for levels of PDE10A with a specific polyclonal
PDE10A antibody (Rbg426v2). GAPDH was used as a loading control.
(E) Quantification of PDE10A levels in striatal lysates. Data are presented as the group mean5 SEM. PDE10A levels were normalized to
GAPDH levels. Normalized data were analyzed by one-way ANOVA with GraphPad Prism v.5.0. PDE10A levels were measured in the
striatum from adult mice of all three genotypes (n ¼ 5 for WT, HET, and KI). Levels of PDE10A p.Tyr97Cys were lower than WT protein
levels. *p < 0.05, ***p < 0.001.
(F) The PDE10A p.Tyr97Cys variant led to a reduction in enzymatic activity. PDE10A enzyme activity was measured in striatal lysates
from adult mice of all three genotypes (n ¼ 5 for WT, HET, and KI). Enzyme activity was measured by means of a scintillation proximity
assay modified from an Amersham Biosciences protocol (TRKQ7090). The assay measures levels of 50 AMP produced when cAMP is
exposed to phosphodiesterase. Data are presented as the group mean 5 SEM and were analyzed by one-way ANOVA with GraphPad
Prism v.5.0. KI mice showed a reduction in PDE10A activity. **p < 0.01, ***p < 0.001.
(G) The PDE10A p.Tyr97Cys variant led to a reduction in downstream signaling. Downstream PDE10A signaling wasmeasured indirectly
by quantifying pCREB levels in striatum from adult mice of all three genotypes (n ¼ 5 for WT, HET, and KI), which had been dosed with
either the selective PDE10A inhibitor MP-10 or vehicle. pCREB levels were higher in both WTand HET animals dosed with the PDE10A
inhibitor than in vehicle-treated animals. Data are presented as the group mean 5 SEM and were analyzed by a paired t test with
GraphPad Prism v.5.0. ***p < 0.001.the mutant variants of human PDE10A in HEK293 cells
revealed lower levels of both mutant proteins than of the
WT. Critically, these observations were reflected in one of
the affected individuals, who had a significant loss of stria-740 The American Journal of Human Genetics 98, 735–743, April 7, 2tal PDE10A signal when investigated with a specific
PDE10A PET ligand in the absence of abnormalities on
MRI. PDE10A levels in striatal tissue lysates from a KI
model were also decreased, leading to a reduced ability to016
degrade cyclic nucleotides. In KI mice, downstream
signaling by PDE10A was decreased, demonstrated by an
absent pCREB response after dosage with a PDE10A
inhibitor.
PDE10A is specifically found at high levels in the striatal
MSNs,3 which receive input from the cortex and thalamus.
MSNs can be divided into two cell types: ‘‘direct pathway’’
MSNs (dMSNs) express dopamine receptor D1 and project
to the globuspallidus internal segment and substantianigra
pars reticulate, whereas ‘‘indirect pathway’’ MSNs (iMSNs)
express dopamine receptor D2 and project indirectly to
the same nuclei via the globus pallidus external segment
and subthalamic nuclei. The classic model predicts that
dMSN activation promotes movement, whereas iMSN acti-
vation leads to inhibition of movement.6 PDE10A is
expressed in both cell types, but pharmacological data
indicate that it might regulate them differentially.27 Phar-
macological inhibition of PDE10A is consistent with the
preferential activation of the indirect pathway,27 which
should result in hypokinetic symptoms. Both Pde10a-
knock-out (KO) mice8 and the Pde10a-KI mice described
here are indeed hypokinetic. However, the affected individ-
uals experience significant hyperkinetic motor symptoms.
This is reminiscent of the phenotypes observed in mouse
models of HD. Individuals affected by HD experience an
initial hyperkinetic phase followed by a hypokinetic
phase.28 However, only some HD models have a hyperki-
netic phase, and it is generally short;29 the lack of recapitu-
lation of motor symptoms between the KI animal and the
affected individuals is thus not unprecedented.
Pharmacological inhibitors of PDE10A have been shown
to reverse a number of phenotypes in HD mouse models.9
However PDE10A levels are reduced in animal models of
HD.30 Furthermore, recent PET studies have shown that in-
dividuals with pathogenicHTT (MIM: 613004) expansions
exhibit reduced levels of striatal PDE10A.31,32 This corre-
lates with disease severity, although significant decreases
in PDE10A have also been seen in asymptomatic individ-
uals carrying pathogenic expansions.31,32 The phenotype
described here results from loss of PDE10A activity in the
striatum, differentiating the effects of selective PDE10A
deficiency from those accompanying striatal cell loss.
Our observations confirm that PDE10A plays a key role
in regulating striato-cortical movement control. Genetic
depletion of PDE10A appears to alter cyclic nucleotide
signaling in theMSNs in humans and thus result in an acti-
vation of motor activity and a hyperkinetic movement
disorder.
These data accord with the recent observation of acti-
vating mutations in adenylyl cyclase 5, ADCY5 (MIM:
600293).33,34 The encoded enzyme converts ATP to pyro-
phosphate and cAMP and is also found at high levels in
the striatum. A hyperkinetic movement disorder was re-
ported in affected individuals, whereas cellular modeling
of the mutations confirmed an increase in cAMP levels.
The variants we report result in a reduced capacity to
degrade cAMP in a cellular model. This is recapitulated inThe Amthe animal model we report. These observations suggest
that modulation of cyclic nucleotide levels in the striatum
plays a key role in movement control.
Ourobservations, particularly the lackofpCREB response
to PDE10A inhibition in our KI mouse model, suggest that
the dose of PDE10A inhibitors might need to be modified
in conditions characterized by reduced PDE10A levels.
The Amaryllis study, a phase II clinical study of a PDE10A
inhibitor, is presently underway in HD. The outcome of
these trials will further inform the clinical relevance and
impact of our observations.
In conclusion, we report a primary loss of PDE10A due
to biallelic PDE10A mutations in humans; this results in
striatal dysfunction, leading to a hyperkinetic movement
disorder. The effects are independent of any other disease
process, including evidence of cell loss. These observations
confirm a key role for PDE10A in the physiology of move-
ment control and a central role for modulation of striatal
cyclic nucleotide levels in this process. They suggest
cellular dysfunction rather than cell death as a cause of
movement disorders.Supplemental Data
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